
Honoured and proud to present the results of INTerpath-001 at ESMO: a randomised controlled phase 3 trial of a #personalised therapeutic cancer vaccine. Individualised neoantigen therapy (intismeran) plus pembrolizumab versus pembrolizumab alone, the current standard of care across the world, in high-risk, early-stage melanoma completely removed by surgery (stage IIB to IIID, and some resected stage IV with no evidence of disease). This is cutting-edge science, and it needs to be understood properly. No hype, no noise. The real data and what they mean for patients. Watch the presentation: melanoma.org.au/news/interpa… At @MelanomaAus our focus is our patients, and curing those we have not yet cured. The therapies my team and I have developed over the last 15 years cure about half of people with stage IV melanoma and prevent stage IV in many with stage II and III. Not everybody, yet. Our multidisciplinary team meeting is world renowned, with leading clinicians with expertise in melanoma and complex skin cancer from diagnosis, management, drug therapies and clinical trials. We discuss the hardest cases, and the evidence we generate shapes clinical practice guidelines around the world. What happens in melanoma impacts other cancers, and we learn from other cancers. Melanoma IS the immunotherapy cancer. #Melanoma #Immunotherapy #INTerpath001 #ESMO26 @myESMO @Sydney_Uni @syd_health @Science_Academy @AAHMS_health @FulbrightAUS @NthSydHealth @ausoftheyear


















